Roth Capital Lifts Earnings Estimates for Nuvectis Pharma

Key Points

• Roth Capital raised their Q3 2025 earnings estimate for Nuvectis Pharma to ($0.21) per share, up from a previous estimate of ($0.22).
• The company recently reported a Q2 EPS of ($0.30), missing the consensus estimate of ($0.25) by $0.05.
• Insiders purchased a total of 39,045 shares worth $314,300 in the last quarter, indicating confidence in the stock's future performance.

Nuvectis Pharma, Inc. (NASDAQ:NVCT - Free Report) - Equities research analysts at Roth Capital boosted their Q3 2025 earnings estimates for Nuvectis Pharma in a note issued to investors on Tuesday, August 12th. Roth Capital analyst J. Aschoff now anticipates that the company will post earnings of ($0.21) per share for the quarter, up from their prior forecast of ($0.22). The consensus estimate for Nuvectis Pharma's current full-year earnings is ($1.01) per share. Roth Capital also issued estimates for Nuvectis Pharma's Q4 2025 earnings at ($0.21) EPS, FY2025 earnings at ($0.97) EPS, FY2026 earnings at ($0.81) EPS, FY2027 earnings at ($0.80) EPS and FY2029 earnings at $3.10 EPS.

Nuvectis Pharma (NASDAQ:NVCT - Get Free Report) last issued its quarterly earnings data on Tuesday, August 5th. The company reported ($0.30) earnings per share for the quarter, missing the consensus estimate of ($0.25) by ($0.05).

Several other analysts also recently commented on the stock. HC Wainwright reduced their price target on shares of Nuvectis Pharma from $15.00 to $10.00 and set a "buy" rating for the company in a research report on Monday, August 4th. Wall Street Zen cut shares of Nuvectis Pharma from a "hold" rating to a "sell" rating in a research note on Sunday, June 29th.

Nuvectis Pharma Price Performance

Shares of NASDAQ:NVCT remained flat at $6.43 during trading on Thursday. 51,266 shares of the stock traded hands, compared to its average volume of 234,726. The stock has a market capitalization of $163.69 million, a PE ratio of -5.50 and a beta of -0.26. Nuvectis Pharma has a twelve month low of $4.44 and a twelve month high of $11.80. The company has a 50-day moving average of $7.65 and a 200 day moving average of $8.26.

Insider Buying and Selling

In other Nuvectis Pharma news, major shareholder Marlio Charles Mosseri acquired 5,603 shares of the stock in a transaction that occurred on Friday, June 20th. The shares were purchased at an average cost of $7.99 per share, with a total value of $44,767.97. Following the purchase, the insider owned 2,981,806 shares in the company, valued at approximately $23,824,629.94. The trade was a 0.19% increase in their ownership of the stock. The purchase was disclosed in a legal filing with the SEC, which is available through the SEC website. Over the last 90 days, insiders have bought 39,045 shares of company stock valued at $314,300. 30.52% of the stock is currently owned by corporate insiders.

Institutional Investors Weigh In On Nuvectis Pharma

A number of large investors have recently added to or reduced their stakes in the business. Police & Firemen s Retirement System of New Jersey purchased a new position in shares of Nuvectis Pharma during the second quarter valued at approximately $28,000. JPMorgan Chase & Co. raised its holdings in Nuvectis Pharma by 3,398.9% in the second quarter. JPMorgan Chase & Co. now owns 6,263 shares of the company's stock valued at $47,000 after buying an additional 6,084 shares during the period. Cubist Systematic Strategies LLC purchased a new position in Nuvectis Pharma in the fourth quarter valued at approximately $34,000. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. acquired a new stake in Nuvectis Pharma in the second quarter valued at approximately $53,000. Finally, Bank of America Corp DE grew its position in Nuvectis Pharma by 417.2% in the second quarter. Bank of America Corp DE now owns 8,565 shares of the company's stock valued at $64,000 after acquiring an additional 6,909 shares in the last quarter. 96.77% of the stock is owned by institutional investors and hedge funds.

About Nuvectis Pharma

Nuvectis Pharma, Inc, a biopharmaceutical company, focuses on the development of precision medicines for the treatment of serious unmet medical needs in oncology. The company's lead product candidate is NXP800, a novel small molecule that is in Phase 1b clinical trials for the treatment of patients with platinum-resistant, ARID1a-mutated ovarian carcinoma.